Condensed Consolidated Statements of Operations (unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net sales		$ 56,067,826	$ 42,889,965	$ 110,736,024	$ 87,373,705
Cost of sales		24,704,294	19,994,229	49,254,885	41,240,751
Gross profit		31,363,532	22,895,736	61,481,139	46,132,954
Operating expenses:
Research and development		1,743,812	1,135,771	3,711,478	2,042,941
Marketing		17,267,461	5,045,945	22,997,714	9,284,962
Selling, general, and administrative		18,505,610	12,333,837	36,143,291	23,571,140
Write-off of acquired Drawbridge in-process research and development		0	1,563,015	0	1,563,015
Income (loss) from operations		(6,153,351)	2,817,168	(1,371,344)	9,670,896
Other (income) expense:
Interest expense, net		(31,514)	(81,256)	(61,671)	(363,901)
Guarantee fees		0	(140,407)	0	(279,271)
Change in fair value of warrant liability		594,899	317,725	528,980	(1,310,026)
Loss On Drawbridge Transaction		0	(165,998)	0	(165,998)
Other income (expense), net		(13,761)	38,143	44,094	38,143
Total other (income) expense, net		549,624	(31,793)	511,403	(2,081,053)
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates		(5,603,727)	2,785,375	(859,941)	7,589,843
Income tax expense		174,553	3,008	207,098	43,538
Net income (loss) before loss from equity interests in unconsolidated affiliates		(5,778,280)	2,782,367	(1,067,039)	7,546,305
Gain (Loss) from equity interests in unconsolidated affiliates		11,037	(3,115,658)	11,037	(3,173,106)
Net income		(5,767,243)	(333,291)	(1,056,002)	4,373,199
Net loss-non-controlling interests		(176,538)	(245,061)	(444,356)	(245,061)
Net income (loss) attributable to Thorne HealthTech, Inc.		(5,590,705)	(88,230)	(611,646)	4,618,260
Undistributed earnings (loss) attributable to Series E convertible preferred stockholders		0	(88,230)	0	4,618,260
Net income attributable to common stockholders		$ (5,590,705)	$ 0	$ (611,646)	$ 0
Earnings per share:
Basic	[1]	$ 0.11	$ 0	$ 0.01	$ 0
Diluted		$ 0.11	$ 0	$ 0.01	$ 0
Weighted average common shares outstanding:
Denominator for basic earnings (loss) per share-weighted average shares (B)	[1]	52,731,604	17,650,035	52,648,653	17,650,035
Diluted	[1]	52,731,604	17,650,035	52,648,653	17,650,035

[1] For the three and six months ended June 30, 2022, 18.1 million and 17.2 million warrants and stock-based awards, respectively, were excluded from the computation of diluted earnings (loss) per share because the effect would have been anti-dilutive under the treasury stock method